Wyles David L
Division of Infectious Diseases, UCSD, 9500 Gilman Drive, MC 0711, La Jolla, CA 92093, USA.
Clin Liver Dis. 2015 Nov;19(4):689-706, vi-vii. doi: 10.1016/j.cld.2015.06.008. Epub 2015 Aug 29.
Hepatitis C virus (HCV) coinfection is prevalent in patients with human immunodeficiency virus (HIV) and has an accelerated disease course. Direct-acting antiviral (DAA) therapies that do not require interferon increase response rates to levels identical to those seen in HCV monoinfection. However, drug-drug interaction between antiretrovirals and HCV medication is the major consideration in deciding on the appropriate HCV therapeutic approach in patients with HIV. This article summarizes the currently available data with HCV DAAs in patients with HIV, and focuses on predicting and managing drug interaction to facilitate successful DAA-based HCV therapy in those with HIV.
丙型肝炎病毒（HCV）合并感染在人类免疫缺陷病毒（HIV）患者中很普遍，并且疾病进展加速。无需干扰素的直接抗病毒（DAA）疗法可将应答率提高到与HCV单一感染患者相同的水平。然而，抗逆转录病毒药物与HCV药物之间的药物相互作用是决定HIV患者合适的HCV治疗方法时的主要考虑因素。本文总结了目前关于HIV患者使用HCV DAA的可用数据，并着重于预测和管理药物相互作用，以促进HIV患者基于DAA的HCV治疗取得成功。
